Induction of human endometrial estradiol dehydrogenase by progestins.
Estradiol-17beta dehydrogenase activity in proliferative human endometrium (average of 1.5 nmole of estrone formed from estradiol/mg protein/h) was stimulated as much as as 6-fold during incubations of tissue slices in culture medium containing progesterone. Stimulation was already detectable at 7 h and the highest activity values were reached at 48-72 h of incubation in the presence of excess progesterone. Maximal stimulation was achieved with concentrations of the hormone of 0.25 mug/ml or higher. At concentrations approximately equal to midluteal plasma levels (20 ng/ml) more than 50% of the maximal response was observed. Norgestrel (17alpha-ethynyl-18-methyl-19-nortestosterone) was also effective in inducing enzymatic activity. The similarity of the effects obtained with progesterone (a possible substrate for estradiol dehydrogenase) and the synthetic progestin indicates that the stimulation of enzymatic activity was not due to substrate induction. Addition of estradiol to the culture medium had no influence on the activity of the enzyme. The induction of estradiol dehydrogenase by progesterone was inhibited by puromycin or actinomycin D. These observations indicate that progestational agents increase the rate of de novo synthesis of the enzyme. Stimulation of endometrial estradiol dehydrogenase was also observed after 2-3 day oral administration of medroxyprogesterone acetate to women in the follicular phase. In contrast, the enzymatic activity in endometrium obtained from women taking estrogens was found to be as low as in normal proliferative tissue. These in vitro and in vivo results point to progesterone as the agent responsible for the 10-fold increase in endometrial estradiol dehydrogenase activity observed during the luteal phase in menstruating women. Data obtained from superfusion studies of estrogen dynamics in endometrium indicate that changes in enzyme concentrations may play a physiologic role in the regulation of tissue levels of estradiol.
D000230:Adenocarcinoma / Q000201:enzymology; D000236:Adenoma / Q000201:enzymology; D046508:Culture Techniques; D003609:Dactinomycin / Q000494:pharmacology; D004717:Endometrium / Q000201:enzymology*; D004790:Enzyme Induction; D004960:Estradiol Dehydrogenases / Q000096:biosynthesis*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases / Q000096:biosynthesis*; D008525:Medroxyprogesterone / Q000494:pharmacology; D008598:Menstruation; D009644:Norgestrel / Q000494:pharmacology; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011691:Puromycin / Q000494:pharmacology; D014594:Uterine Neoplasms / Q000201:enzymology
D004966:Estrogens, Conjugated (USP); D003609:Dactinomycin; D009644:Norgestrel; D011691:Puromycin; D011374:Progesterone; D006913:Hydroxysteroid Dehydrogenases; D004960:Estradiol Dehydrogenases; D008525:Medroxyprogesterone